FinData: News for NASDAQ, AVII - AVI BioPharma Inc.

Thursday, 20 June 2013

AVI BioPharma Inc.

Recent News

Sarepta Therapeutics Inc Announces Pricing Of $125 Million Public Offering Of Common Stock
03:15 | 14/12/12

Reuters Key Development
Sarepta Therapeutics Inc Announces Pricing Of $125 Million Public Offering Of Common Stock more»
Sarepta Therapeutics Announces Public Offering Of Common Shares - Quick Facts
10:14 | 13/12/12

RTT News
Sarepta Therapeutics Inc. (SRPT: Quote) said Wednesday it is offering to sell shares of its common stock in an underwritten public offering. more»
Sarepta Therapeutics (SRPT) Announces Common Stock Offering
10:08 | 13/12/12

StreetInsider.com (subscription)
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. more»
Sarepta Therapeutics Inc Announces Proposed Public Offering Of Common Stock
10:01 | 13/12/12

Reuters Key Development
Sarepta Therapeutics Inc Announces Proposed Public Offering Of Common Stock more»
Sarepta Therapeutics (SRPT) Moves Higher; Brother 'Max' On Pace with Others ...
09:00 | 11/12/12

StreetInsider.com (subscription)
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is seeing a late-day pop which could be related to an updated article on the case of the brothers with Duchenne muscular dystrophy - one taking the drug and the other not. more»
Sarepta Therapeutics shares after treatment update
08:32 | 8/12/12

Businessweek
Shares of Sarepta Therapeutics Inc. slid Friday, even though the company announced more positive results from a study of its Duchenne muscular dystrophy drug eteplirsen. more»
Sarepta Therapeutics Inc Announces Continued Benefit On Walking Test Through 62 Weeks In Phase IIb Open-Label Extension Study of Eteplirsen In Duchenne Muscular Dystrophy
02:30 | 8/12/12

Reuters Key Development
Sarepta Therapeutics Inc Announces Continued Benefit On Walking Test Through 62 Weeks In Phase IIb Open-Label Extension Study of Eteplirsen In Duchenne Muscular Dystrophy more»
These Biotech Stocks Are Set for Attention at the dbAccess BioFEST Conference
04:45 | 29/11/12

SmallCap Network
Biotech stocks BioMarin Pharmaceutical (BMRN), NPS Pharmaceuticals (NPSP), Aegerion Pharmaceuticals (AEGR) and Sarepta Therapeutics (SRPT) are some of the more interesting attendee companies at the upcoming dbAccess BioFEST Conference. By John Udovich ... more»
Sarepta Therapeutics to Present Company Overview at the Deutsche Bank 2012 ...
10:06 | 28/11/12

MarketWatch
CAMBRIDGE, MA, Nov 27, 2012 (MARKETWIRE via COMTEX) -- Sarepta Therapeutics (NASDAQ:SRPT) , a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST ... more»
Dominick & Dominick Assumes Coverage on Sarepta Therapeutic (SRPT)
09:43 | 28/11/12

Daily Political
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases. more»

Global Indices

Code	Last	Change
NZ50	4,446	17	0.37%
COMP	3,482	30	0.87%
DJI	15,318	138	0.91%
SP500	1,630	22	1.30%
DAX	7,789	91	1.15%
FTSE	6,374	44	0.69%
NI225	12,494	22	0.18%
TWI	73.59	0.45	0.60%

More news...

No news available...

Currencies

Code	Last	Change
EURUSD	1.328	0.011	0.79%
NZDUSD	0.7881	0.0097	1.22%
AUDUSD	0.9337	0.0133	1.40%
NZDAUD	0.8440	0.0011	0.13%